Randomized clinical trial of single-dose antibiotic prophylaxis for non-reconstructive breast surgery.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 16989011.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The aim of this randomized clinical trial was to determine whether a single intravenous dose of 2 g flucloxacillin could prevent wound infection after primary non-reconstructive breast surgery. The study included 618 patients undergoing local excision (n = 490), mastectomy (n = 107) or microdochectomy (n = 21). Patients were randomized to receive either a single dose of flucloxacillin immediately after the induction of anaesthesia or no intervention. Wound morbidity was monitored by an independent research nurse for 42 days after surgery. The incidence of wound infection was similar in the two groups: 10 of 311 (3.2 percent) in the flucloxacillin group and 14 of 307 (4.6 percent) in the control group (chi(2) = 0.75, P = 0.387; relative risk 0.71, 95 percent confidence interval 0.32 to 1.53). The groups also had similar wound scores and rates of moderate or severe cellulitis. Wound infection presented a median of 16 days after surgery. The administration of a single dose of flucloxacillin failed to reduce the rate of wound infection after non-reconstructive breast surgery.
Medical subject headings
- Anti-Bacterial Agents
- Antibiotic Prophylaxis
- Floxacillin
- Mammaplasty
- Surgical Wound Infection